Molecular and Cellular Biochemistry

, Volume 178, Issue 1–2, pp 127–133 | Cite as

Protection by ebselen against cisplatin-induced nephrotoxicity: Antioxidant system

  • K. Husain
  • C. Morris
  • C. Whitworth
  • G.L. Trammell
  • L.P. Rybak
  • S.M. Somani


This study was designed to investigate the cisplatin-induced alteration in renal antioxidant system and the nephroprotection with ebselen. Male Wistar rats were injected with (1) vehicle control; (2) cisplatin; (3) ebselen; and (4) cisplatin plus ebselen. Rats were sacrificed three days post-treatment and plasma as well as kidney were isolated and analyzed. Plasma creatinine increased 598% following cisplatin administration alone which decreased by 158% with ebselen pretreatment. Cisplatin-treated rats showed a depletion of renal glutathione (GSH) levels (52% of control), while cisplatin plus ebselen injected rats had GSH values close to the controls. Antioxidant enzymes superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GSH-Px) activities decreased 38, 75 and 62% of control, respectively, and malondialdehyde (MDA) levels increased 174% of control following cisplatin administration, which were restored to control levels after ebselen treatment. The renal platinum level did not significantly change with ebselen pretreatment. This study suggests that the protection offered by ebselen against cisplatin-induced nephrotoxicity is partly related to the sparing of antioxidant system.

cisplatin ebselen glutathione antioxidant enzymes lipid peroxidation nephrotoxicity 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Cozzaglio L, Doci R, Colla G, Zunino F, Casciarri G, Gennari L: A feasibility study of highdose cisplatin and 5-fluorouracil with glutathione protection in the treatment of advanced colorectal cancer. Tumori 76: 590–594, 1990Google Scholar
  2. 2.
    Di Re F, Bohm S, Oriana S, Spatti GB, Zunino F: Efficacy and safety of high-dose cisplatin and cyclophosphamide with glutathione protection in the treatment of bulky advanced epithelialovarian cancer. Can Chemother Pharmacol 25: 355–360, 1990Google Scholar
  3. 3.
    Gandara DR, Perez EA, Weibe V, DeGregorio MW: Cisplatin chemoprotection and rescue: Pharmacologic modulation of toxicity. Semin Oncol 18: 49–55, 1991Google Scholar
  4. 4.
    Bodenner DL, Dedon PC, Keng PC, Katz JC, Borch RF: Selective protection against cisplatin induced toxicity in kidney, gut, and bone marrow by DDTC. Cancer Res 46: 2751–2755, 1986Google Scholar
  5. 5.
    Hamers FPT, Brakkee JH, Cavalletti E, Tedeschi M, Marmonti L, Pezzoni G, Neijt JP, Gispen WH: Reduced glutathione protects against cisplatin-induced neurotoxicity in rats. Cancer Res 53: 544–549, 1993Google Scholar
  6. 6.
    Rybak LP, Ravi R, Somani SM: Mechanism of protection by diethyldithiocarbamate against cisplatin ototoxicity: Antioxidant system. Fund Appl Toxicol 26: 293–300, 1995Google Scholar
  7. 7.
    Wolfgang GHI, Dominick MA, Walsh KM, Hoeschele JD, Pegg DG: Comparative nephrotoxicity of a novel platinum compound, cisplatin and carboplatin in male Wistar rats. Fundam Appl Toxicol 22: 73–79, 1994Google Scholar
  8. 8.
    Tognella S: Pharmacological interventions to reduce platinum-induced toxicity. Cancer Treat Rev 17: 139–142, 1990Google Scholar
  9. 9.
    Hidaka S, Tsurupka M, Funakoshi T, Shimada H, Kivozumi M, Kolima S: Protective effects of dithiocarbamates against renal toxicity of cisdiamminedichloroplatinum in rats. Renal Failure 16: 337–349, 1994Google Scholar
  10. 10.
    Somani SM, Ravi R, Rybak LP: Diethyldithiocarbamate protection against cisplatin nephrotoxicity, Antioxidant System. Drug Chem Toxicol 18: 151–170, 1995Google Scholar
  11. 11.
    Qazi R, Chang AY, Borch RF, Montine T, Dedon P, Loughner J, Bennett JM: Phase I clinical and pharmacokinetic study of diethyldithiocarbamate as a chemoprotector from toxic effects of cisplatin. J Natl Can Inst 80: 1486–1488, 1988Google Scholar
  12. 12.
    Walker EM Jr, Fazekas-May MA, Heard KW, Yee S, Montague D, Jones MM: Prevention of cisplatin-induced toxicity by selected dithiocarbamates. Ann Clin Lab Sci 24: 121–133, 1994Google Scholar
  13. 13.
    Markman M, D'Acquito R, Iannoti N, Kois H, Hakes T, Bajorin D, Bosl G, Reichman B, Casper E, Magill G: Phase I trial of high dose intravenous cisplatin with simultaneous intravenous sodium thiosulphate. J Can Res Clin Oncol 117: 151–155, 1991Google Scholar
  14. 14.
    Yuhas JM., Culo F: Selective inhibition of the nephrotoxicity of cisdichlorodiammineplatinum (II) by WR-2721 without altering its antitumor properties. Can Treat Rep 64: 57–64, 1980Google Scholar
  15. 15.
    Babu E, Gopal Krishnan VK, Sriganth INP, Gopal Krishnan R, Sakthisekaran D: Cisplatin induced nephrotoxicity and the modulating effect of glutathione ester. Mol Cell Biochem 144: 7–11, 1995Google Scholar
  16. 16.
    Fontanelli R, Spatti G, Raspagliesi F, Zunino F, DiRe F: A preoperative single course of high dose cisplatin and bleomycin with glutathione protection in bulky stage IB/II carcinoma of the cervix. Ann Oncol 3: 117–121, 1992Google Scholar
  17. 17.
    Zunino F, Pratesi G, Micheloni A, Cavalletti E, Sala F, Tofanetti O: Protective effect of reduced glutahione against cisplatin-induced renal and systemic toxicity and its influence on the therapeutic activity of the antitumor drug. Chem Biol Interact 70: 89–101, 1989Google Scholar
  18. 18.
    Heyman SN, Spokes K, Egorin MJ, Epstein F: Glycine reduces early renal parenchymal uptake of cisplatin. Kidney Int 43: 1226–1228, 1993Google Scholar
  19. 19.
    Basinger MA, Jones MM, Holscher MA: L-methionine antagonism of cis-platinum-induced nephrotoxicity. Toxicol Appl Pharmacol 103: 1–15, 1990Google Scholar
  20. 20.
    Boogaard PJ, Lempers EL, Mulder GJ, Meerman JHN: 4-methylthiobenzoic acid reduces cisplatin nephrotoxicity in rats without compromising anti-tumour activity. Biochem Pharmacol 41: 1997–2003, 1991Google Scholar
  21. 21.
    Husain K, Morris C, Whitworth C, Trammell GL, Rybak LP, Somani SM: 4-methylthiobenzoic acid protection against cisplatic nephrotoxicity: Antioxidant system. Fundam Appl Toxicol 32: 278–284, 1996Google Scholar
  22. 22.
    Jones MM, Basinger MA, Holscher MA: Thioether suppression of cisplatin nephrotoxicity in the rat. Anticancer Res 11: 449–454, 1991Google Scholar
  23. 23.
    Esposito M, Viale M, Vannozi MO, Zicca A, Cadoni A, Merlo F, Gogioso L: Effect of the antiarrhythmic drug procainamide on the toxicity and antitumor activity of cis diamminedichloroplatinum (II). Toxicol Appl Pharamcol 140: 370–377, 1996Google Scholar
  24. 24.
    Esposito M, Fulco RA, Collecchi P, Zicca A, Cadoni A, Merlo F, Rosso R, Sobero A: Improved therapeutic index of cisplatin by procaine hydrochloride. J Natl Cancer Int 82: 677–684, 1990Google Scholar
  25. 25.
    Uslu R, Bonavida B: Involvement of the mitochondrion respiratory chain in the synergy achieved by treatment of human ovarian carcinoma cell lines with both tumor necrosis factor-alpha and cis-diammine dichloroplatinum. Cancer 77: 725–732, 1996Google Scholar
  26. 26.
    Sugihara K, Nakano S, Koda M, Tanaka K, Fukuishi N, Gemba M: Stimulatory effect of cisplatin on production of lipid peroxidation in renal tissues. Jpn J Pharmacol 43: 247–252, 1987Google Scholar
  27. 27.
    Hannemann J, Baumann K: Cisplatin-induced lipid peroxidation and decrease of gluconeogenesis in rat kidney cortex: Different effects of antioxidants and radical scavengers. Toxicology 51: 119–132, 1988Google Scholar
  28. 28.
    McGuiness JE, Proctor P, Demopoulos H: Ameloriation of cisplatinum nephrotoxicity by orgotein (superoxide dismutase). Physiol Chem Phys 10: 269–277, 1978Google Scholar
  29. 29.
    Baldew GS, Mol JG, de-Kanter FJ, van-Barr B, de-Goeij JJ, Vermeulen NP: The mechanism of interaction between cisplatin and selenite. Biochem Pharmacol 41: 1429–1437, 1991Google Scholar
  30. 30.
    Bull JMC, Strebel F, Sunderland BA, Bulger RE, Edwards M, Siddik ZH, Newman RA: O-(β-hydroxyethyl)-rutoside-mediated protection of renal injury associated with cis diamminedichloroplatinum (II)/hyperthermia treatment. Cancer Res 48: 2239–2244, 1988Google Scholar
  31. 31.
    Maiorino M, Roveri A, Ursini F: Antioxidant effect of ebselen (Pz 51): Peroxidase mimetic activity on phospholipid and cholesterol hydroperoxides vs free radical scavenger activity. Arch Biochem Biophys 295: 404–409, 1992Google Scholar
  32. 32.
    Muller A, Cadenas E, Graf P, Sies H: Glutathione peroxidase like activity in vitro and antioxidant capacity of PZ51 (ebselen). Biochem Pharmacol 33: 3235–3239, 1984Google Scholar
  33. 33.
    Baldew GW, McVie JW, Vander Valk MA, Los G, DeGoeij JJM, Vermeulen NPE: Selective reduction of cis-diamminedichloroplatinum (II) nephrotoxicity by ebselen. Cancer Res 50: 7031–7036, 1990Google Scholar
  34. 34.
    McFariss W, Reed DJ: High performance liquid chromatography of thiols and disulfides: Dinitrophenol derivatives. Meth Enzymol 143: 101–109, 1987Google Scholar
  35. 35.
    Misra HP, Fridovich I: The role of superoxide anion in the autooxidation of epinephrine and a simple assay for superoxide-dismutase. J Biol Chem 247: 3170–3175, 1972Google Scholar
  36. 36.
    Aebi H: Catalase in vitro. Meth Enzymol 105: 121–126, 1984Google Scholar
  37. 37.
    Flohe L, Gunzler W: Assays of glutathione peroxidase. Meth Enzymol 105: 114–121, 1994Google Scholar
  38. 38.
    Ohkawa H, Ohishi N, Yagi K: Assay for lipid peroxides in animals and tissues by thiobarbituric acid reaction. Anal Biochem 95: 351–358, 1979Google Scholar
  39. 39.
    Litterst CL, Schweitzer VG: Covalent binding of platinum to renal protein from sensitive and resistant guinea pigs treated with cisplatin: Possible role in nephrotoxicity. Res Commun Chem Pathol Pharmacol 61: 35–48, 1988Google Scholar
  40. 40.
    Read SM, Northcole DH: Minimization of variation in the response to different protein of the Coomassie blue G dye-binding assay for protein. Anal Biochem 116: 53–64, 1981Google Scholar
  41. 41.
    DeWoskin RS, Riviere JE: Cisplatin-induced loss of kidney copper and nephrotoxicity is ameliorated by single dose diethyldithiocarbamate, but not mesna. Toxicol Appl Pharmacol 112: 182–189, 1992Google Scholar
  42. 42.
    Ravi R, Somani SM, Rybak LP: Mechanism of cisplatin ototoxicity: Antioxidant system. Pharmacol Toxicol 76: 386–394, 1995Google Scholar
  43. 43.
    Mistry P, Merazga Y, Spargo DJ, Riley PA, McBrien DCH: The effects of cisplatin on the concentration of protein thiols and glutathione in the rat kidney. Cancer Chemother Pharmacol 28: 277–282, 1991Google Scholar
  44. 44.
    Ban M, Hettich D, Huguet N: Nephrotoxicity mechanism of cisplatinum (II) diamine dichloride in mice. Toxicol Lett 71: 161–168, 1994Google Scholar
  45. 45.
    Nakano S, Gemba M: Potentiation of cisplatin-induced lipid peroxidation in kidney cortical slices by glutathione depletion. Jpn J Pharmacol 50: 87–92, 1988Google Scholar
  46. 46.
    Kameyama Y, Gemba M: Cisplatin-induced injury to calcium uptake by mitochondria in glutathione-depleted slices of rat kidney cortex. Jpn J Pharmacol 55: 174–176, 1991Google Scholar
  47. 47.
    Zhang JG, Lindup WE: Role of mitochondria in cisplatin induced oxidative damage exhibited by rat renal cortical slices. Biochem Pharmacol 45: 2215–2222, 1993Google Scholar
  48. 48.
    Younes M, Siegers CP: Mechanistic aspects of enhanced lipid peroxidation following glutathione depletion in vivo. Chem Biol Interact 34: 257–266, 1981Google Scholar
  49. 49.
    Sharrna RP: Interactions of cisplatin with cellular zinc and copper in liver and kidney tissues. Pharmacol Res Commun 17: 197–206, 1985Google Scholar
  50. 50.
    Sinet PM, Carber P: Inactivation of the human CuZn-superoxide dismutase during exposure to O·2 and H2O2. Arch Biochem Biophys 212: 411–416, 1981Google Scholar

Copyright information

© Kluwer Academic Publishers 1998

Authors and Affiliations

  • K. Husain
    • 1
  • C. Morris
    • 2
  • C. Whitworth
    • 2
  • G.L. Trammell
    • 3
  • L.P. Rybak
    • 2
  • S.M. Somani
    • 1
  1. 1.Department of PharmacologySouthern Illinois University School of MedicineSpringfieldUSA
  2. 2.Department of SurgerySouthern Illinois University School of MedicineSpringfieldUSA
  3. 3.Department of ChemistryUniversity of Illinois at SpringfieldSpringfieldUSA

Personalised recommendations